pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,151 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT967Endpoints741BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5600Rare Disease1249Cardiology1051Hematology933Immunology925Vaccines812Pulmonology
  • Supreme Court preserves mail access for abortion pill
    The Supreme Court will continue to allow the abortion pill mifepristone to be distributed by mail, at least for now. The Thursday ruling maintains mifepristone's current safety protocols while liti…
    Endpoints · 3mo ago↗ source
  • AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC
    AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.
    onclive · 3mo ago↗ source
  • Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis
    Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.
    onclive
← prev
page 34 of 47
next →
65
fda recalls43
fda medwatch30
fda press25
776
Psychiatry & CNS688
Ophthalmology343
Endocrinology & Metabolism338
Pain338
Infectious Disease327
· 3mo ago
↗ source
  • Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Prevention
    Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.
    onclive · 3mo ago↗ source
  • IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026
    Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.
    onclive · 3mo ago↗ source
  • Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
    Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
    onclive · 3mo ago↗ source
  • #ASGCT26: Encoded's gene therapy reduced seizures in Dravet syndrome
    A gene therapy designed by Encoded Therapeutics reduced seizures by 76% in children with Dravet syndrome, a severe neurodevelopmental disorder. The remarkable reduction was observed only in three p…
    Endpoints · 3mo ago↗ source
  • #ASGCT26 dispatch: In vivo CAR-T is everywhere
    BOSTON — Greetings from Boston, where I’ve been on the ground covering the American Society of Gene & Cell Therapy’s annual meeting all week. It’s a crucial moment for the field. Genetic medicine d…
    Endpoints · 3mo ago↗ source
  • Imaging Clues That Raise Suspicion for Diffuse Midline Glioma
    n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG.
    onclive · 3mo ago↗ source
  • Two Diseases That Share a Name — Defining Glioblastoma and Diffuse Midline Glioma Under the 2021 WHO Classification
    In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.
    onclive · 3mo ago↗ source
  • Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance
    Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.
    onclive · 3mo ago↗ source
  • Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC
    Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.
    onclive · 3mo ago↗ source
  • Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
    The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.
    onclive · 3mo ago↗ source
  • Drugmakers have to go through rigorous tests to get a lower tariff rate
    Landing a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive or…
    Endpoints · 3mo ago↗ source
  • Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
    A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.
    onclive · 3mo ago↗ source
  • Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data
    💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform. The San Diego and Shanghai biotech has raised $95 mil…
    Endpoints · 3mo ago↗ source
  • REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer
    Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.
    onclive · 3mo ago↗ source
  • AstraZeneca follows Merck with Phase 3 win in bladder cancer
    A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…
    Endpoints · 3mo ago↗ source
  • MacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack
    Plus, news about Bavarian Nordic and OrganaBio’s new CDMO subsidiary: 🏭 Bora buys MacroGenics' manufacturing operations: MacroGenics is selling its clinical and commercial drug substance productio…
    Endpoints · 3mo ago↗ source
  • Clinical Implementation and Surveillance Strategies
    onclive · 3mo ago↗ source
  • Case Introduction and ctDNA as Emerging Risk Factor
    onclive · 3mo ago↗ source
  • How Penn Medicine plans to use AI to train their doctors
    Physicians at Penn Medicine said they're thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine won in January through an education grant program with ...
    Endpoints · 3mo ago↗ source
  • ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
    Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.
    onclive · 3mo ago↗ source
  • MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies
    Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.
    onclive · 3mo ago↗ source
  • Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question
    New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.
    onclive · 3mo ago↗ source